BIOMAT Database Logo BIOMAT Database Logo

Comparison of a recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage. 1990

Y Poovorawan, and S Sanpavat, and W Pongpunlert, and S Chumdermpadetsuk, and P Sentrakul, and S Chitinand, and R Sakulramrung, and Y Tannirundorn
Department of Pediatrics, Obstetrics and Gynaecology, Faculty of Medicine, Chulalongkorn University and Hospital, Bangkok, Thailand.

The protective efficacy of a recombinant DNA yeast-derived hepatitis B vaccine was assessed alone or in combination with hepatitis B immune globulin (HBIg) in neonates born to surface antigen (HBsAg)-positive and e antigen (HBeAg)-positive mothers. Neonates received either a 10 micrograms dose of vaccine alone or the same dose of vaccine plus 0.5 ml HBIg within 12 h of birth. All infants subsequently received 10 micrograms of vaccine at 1, 2 and 12 months. Only two of the 58 (3.4%) newborns of HBsAg-positive/HBeAg-positive mothers receiving vaccine alone became chronically infected with hepatitis B virus (HBV) while all infants administered vaccine + HBIg were protected. These results indicate that although the administration of HBIg can increase the protection rate, the use of vaccine without concomitant administration of HBIg according to the above schedule could considerably reduce the risk of perinatal HBV transmission.

UI MeSH Term Description Entries
D007115 Immunization Schedule Schedule giving optimum times usually for primary and/or secondary immunization. Immunization Schedules,Schedule, Immunization,Schedules, Immunization
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008431 Maternal-Fetal Exchange Exchange of substances between the maternal blood and the fetal blood at the PLACENTA via PLACENTAL CIRCULATION. The placental barrier excludes microbial or viral transmission. Transplacental Exposure,Exchange, Maternal-Fetal,Exposure, Transplacental,Maternal Fetal Exchange
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D002353 Carrier State The condition of harboring an infective organism without manifesting symptoms of infection. The organism must be readily transmissible to another susceptible host. Asymptomatic Carrier State,Asymptomatic Infection Carrier,Inapparent Infection Carrier,Presymptomatic Carrier State,Presymptomatic Infection Carrier,Super-spreader Carrier,Superspreader Carrier,Asymptomatic Carrier States,Asymptomatic Infection Carriers,Carrier State, Asymptomatic,Carrier State, Presymptomatic,Carrier States,Carrier, Super-spreader,Carrier, Superspreader,Carriers, Super-spreader,Carriers, Superspreader,Inapparent Infection Carriers,Infection Carrier, Asymptomatic,Infection Carrier, Inapparent,Infection Carrier, Presymptomatic,Presymptomatic Carrier States,Presymptomatic Infection Carriers,Super spreader Carrier,Super-spreader Carriers,Superspreader Carriers
D005260 Female Females
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006510 Hepatitis B Antibodies Antibodies to the HEPATITIS B ANTIGENS, including antibodies to the surface (Australia) and core of the Dane particle and those to the "e" antigens. Anti-Australia Antigens,Anti-HBAg,Anti-Hepatitis B Antigens,Anti HBAg,Hepatitis B Virus Antibodies,Anti Australia Antigens,Anti Hepatitis B Antigens,Antibodies, Hepatitis B,Antigens, Anti-Australia,Antigens, Anti-Hepatitis B,B Antibodies, Hepatitis,B Antigens, Anti-Hepatitis,HBAg, Anti
D006511 Hepatitis B Antigens Antigens of the virion of the HEPATITIS B VIRUS or the Dane particle, its surface (HEPATITIS B SURFACE ANTIGENS), core (HEPATITIS B CORE ANTIGENS), and other associated antigens, including the HEPATITIS B E ANTIGENS. HBAg,Hepatitis B Antigen,Antigen, Hepatitis B,Antigens, Hepatitis B,B Antigen, Hepatitis,B Antigens, Hepatitis

Related Publications

Y Poovorawan, and S Sanpavat, and W Pongpunlert, and S Chumdermpadetsuk, and P Sentrakul, and S Chitinand, and R Sakulramrung, and Y Tannirundorn
Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission.
May 1987, JAMA,
Y Poovorawan, and S Sanpavat, and W Pongpunlert, and S Chumdermpadetsuk, and P Sentrakul, and S Chitinand, and R Sakulramrung, and Y Tannirundorn
Use of hepatitis B vaccine alone or in combination with hepatitis B immunoglobulin for immunoprophylaxis of perinatal hepatitis B infection.
October 1992, Journal of tropical pediatrics,
Y Poovorawan, and S Sanpavat, and W Pongpunlert, and S Chumdermpadetsuk, and P Sentrakul, and S Chitinand, and R Sakulramrung, and Y Tannirundorn
Hepatitis B prevention strategies: a benefit-cost analysis of immune serum globulin, hepatitis B immune globulin, and hepatitis B vaccine in the military.
January 1986, American journal of preventive medicine,
Y Poovorawan, and S Sanpavat, and W Pongpunlert, and S Chumdermpadetsuk, and P Sentrakul, and S Chitinand, and R Sakulramrung, and Y Tannirundorn
Prevention of hepatitis B by recombinant DNA hepatitis B vaccine.
January 1986, The Netherlands journal of medicine,
Y Poovorawan, and S Sanpavat, and W Pongpunlert, and S Chumdermpadetsuk, and P Sentrakul, and S Chitinand, and R Sakulramrung, and Y Tannirundorn
Reduced doses of hepatitis B immune globulin in the prevention of perinatal transmission of hepatitis B.
April 1987, Journal of medical virology,
Y Poovorawan, and S Sanpavat, and W Pongpunlert, and S Chumdermpadetsuk, and P Sentrakul, and S Chitinand, and R Sakulramrung, and Y Tannirundorn
Efficacy of hepatitis B immune globulin in prevention of perinatal transmission of the hepatitis B virus.
August 1984, Gastroenterology,
Y Poovorawan, and S Sanpavat, and W Pongpunlert, and S Chumdermpadetsuk, and P Sentrakul, and S Chitinand, and R Sakulramrung, and Y Tannirundorn
Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine.
November 1983, Lancet (London, England),
Y Poovorawan, and S Sanpavat, and W Pongpunlert, and S Chumdermpadetsuk, and P Sentrakul, and S Chitinand, and R Sakulramrung, and Y Tannirundorn
Review: hepatitis B immune globulin for prevention of hepatitis B infection.
July 2007, Journal of medical virology,
Y Poovorawan, and S Sanpavat, and W Pongpunlert, and S Chumdermpadetsuk, and P Sentrakul, and S Chitinand, and R Sakulramrung, and Y Tannirundorn
Letter: Prevention of hepatitis B with "immune" globulin.
March 1976, The New England journal of medicine,
Y Poovorawan, and S Sanpavat, and W Pongpunlert, and S Chumdermpadetsuk, and P Sentrakul, and S Chitinand, and R Sakulramrung, and Y Tannirundorn
Recombinant hepatitis B vaccine for prevention of hepatitis B infection.
July 1990, The Journal of the Association of Physicians of India,
Copied contents to your clipboard!